log  
logo
a Journal of Postdoctoral Research and Postdoctoral Affairs.
logo
    ISSN : 2328-9791
left right
 
 
Development and preclinical testing of a novel antimicrobial peptide to treat Pseudomonas
     
 
Author(s) : Mangoni ML, Cappiello F, Casciaro B, Luca V, Chen C, Lin Q, Di PY
Address : Department of Biochemical Sciences, Sapienza University of Rome, Rome-Italy, Department of Environmental and Occupational Health, University of Pittsburgh, USA
Sapienza University of Rome, University of Pittsburgh
Info@PostdocJournal.Com

Background. Pseudomonas aeruginosa is the most predominant lung pathogen in patients with cystic fibrosis (CF). It is quite difficult to eradicate because of its acquired resistance to most available antibiotics and ability to form sessile communities or biofilms, in a protective extracellular matrix. Cationic antimicrobial peptides (AMPs) hold promise as future anti-infective agents.

Hypothesis and objectives. Our objective was to develop a short-sized AMP from frog skin, Esc(1-21) and/or its diastereomer containing two D-amino acids, for treatment of P. aeruginosa lung infections. To this aim: (i) an in-vitro analysis of the anti-pseudomonal, anti-inflammatory, wound healing properties of the two peptides, and (ii) preclinical testing to establish both the peptides' safety profiles and therapeutic dosages were performed.

 
btm
 
Discussion Board
 
Comments
 
     
btm
 
 
 
top
 
 
 
 
btm
top
btm

 
submit_article Announcements
 
submit_article Submit Your Article
 
submit_article Post your Job
footer
 
 
home phone mail info@postdocjournal.com
 
twitter facebook social icon Social link You Tube sky
Click Here